{"id":"anti-covid-19-human-immunoglobulin","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This monoclonal antibody therapy is designed to provide immediate protection against COVID-19 by targeting the spike protein of the virus, thereby preventing it from entering host cells. The human immunoglobulin is derived from donors who have been immunized against COVID-19, providing a pool of pre-formed antibodies that can neutralize the virus.","oneSentence":"Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:59.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in individuals at high risk of severe disease"}]},"trialDetails":[{"nctId":"NCT06965751","phase":"PHASE1","title":"A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2025-06-27","conditions":"COVID-19 Infection","enrollment":32},{"nctId":"NCT06703034","phase":"NA","title":"Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-12-02","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04661839","phase":"PHASE1","title":"A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2020-12-24","conditions":"COVID-19","enrollment":28},{"nctId":"NCT05142306","phase":"PHASE1","title":"A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2021-12-07","conditions":"SARS-CoV-2 Infection","enrollment":23},{"nctId":"NCT04592549","phase":"PHASE1","title":"Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":48},{"nctId":"NCT04516564","phase":"PHASE1","title":"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","status":"COMPLETED","sponsor":"Akesobio Australia Pty Ltd","startDate":"2020-09-28","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":29},{"nctId":"NCT04370834","phase":"PHASE2","title":"Tocilizumab for Patients With Cancer and COVID-19 Disease","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-28","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia","enrollment":1},{"nctId":"NCT04447469","phase":"PHASE2, PHASE3","title":"Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation","status":"COMPLETED","sponsor":"Kiniksa Pharmaceuticals International, plc","startDate":"2020-07-28","conditions":"COVID","enrollment":814},{"nctId":"NCT04359810","phase":"PHASE2","title":"Plasma Therapy of COVID-19 in Severely Ill Patients","status":"COMPLETED","sponsor":"Max O'Donnell","startDate":"2020-04-21","conditions":"SARS-CoV-2 Infection","enrollment":223},{"nctId":"NCT04390503","phase":"PHASE2","title":"Convalescent Plasma for Early Treatment of COVID-19","status":"TERMINATED","sponsor":"Andrew Eisenberger","startDate":"2021-03-12","conditions":"SARS-CoV 2, COVID-19","enrollment":223},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT06452056","phase":"","title":"COVID-19 SARS-CoV-2 RAST Study","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-01-07","conditions":"SARS-CoV2 Infection","enrollment":337},{"nctId":"NCT05679479","phase":"PHASE3","title":"Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19","status":"COMPLETED","sponsor":"Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd","startDate":"2024-01-19","conditions":"COVID-19","enrollment":108},{"nctId":"NCT05813587","phase":"PHASE3","title":"To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19","status":"COMPLETED","sponsor":"Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd","startDate":"2023-03-23","conditions":"Post-COVID-19","enrollment":121},{"nctId":"NCT05679492","phase":"PHASE3","title":"Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19","status":"WITHDRAWN","sponsor":"Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd","startDate":"2023-05-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04206332","phase":"PHASE1","title":"Trial to Evaluate CIS43LS in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-07","conditions":"Malaria","enrollment":71},{"nctId":"NCT05142527","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19","status":"WITHDRAWN","sponsor":"Alachua Government Services, Inc.","startDate":"2023-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05706038","phase":"","title":"Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-04-27","conditions":"Inflammatory Bowel Diseases, Rheumatic Disorder","enrollment":49},{"nctId":"NCT04847141","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2021-04-28","conditions":"COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","enrollment":465},{"nctId":"NCT04983446","phase":"PHASE2","title":"In-patient COVID-19 Study of Intranasal Foralumab","status":"WITHDRAWN","sponsor":"Tiziana Life Sciences LTD","startDate":"2022-04-30","conditions":"Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection","enrollment":""},{"nctId":"NCT05338736","phase":"","title":"Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2022-04-01","conditions":"SARS CoV 2 Infection, COVID-19","enrollment":45},{"nctId":"NCT04780321","phase":"PHASE1, PHASE2","title":"JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-10-30","conditions":"COVID-19","enrollment":62},{"nctId":"NCT05358873","phase":"NA","title":"Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2022-04-20","conditions":"SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease","enrollment":50},{"nctId":"NCT04932850","phase":"PHASE1","title":"Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.","status":"COMPLETED","sponsor":"Toscana Life Sciences Sviluppo s.r.l.","startDate":"2021-03-01","conditions":"COVID-19 Virus Disease","enrollment":30},{"nctId":"NCT04323800","phase":"PHASE2","title":"Convalescent Plasma to Stem Coronavirus (CSSC-001)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-06-10","conditions":"Coronavirus, Convalescence","enrollment":180},{"nctId":"NCT04469179","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","status":"UNKNOWN","sponsor":"SAb Biotherapeutics, Inc.","startDate":"2020-08-20","conditions":"COVID-19, SARS-CoV2","enrollment":21},{"nctId":"NCT04590794","phase":"","title":"SuPAR in Adult Patients With Covid-19","status":"COMPLETED","sponsor":"University of Thessaly","startDate":"2020-10-11","conditions":"Covid19","enrollment":767},{"nctId":"NCT04931238","phase":"PHASE2","title":"Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01-20","conditions":"COVID-19, SARS-CoV-2","enrollment":200},{"nctId":"NCT04895007","phase":"","title":"Comparative Evaluation of Covid-19 Vaccines Response","status":"UNKNOWN","sponsor":"Karamanoğlu Mehmetbey University","startDate":"2021-06-01","conditions":"COVID-19 Vaccines","enrollment":1500},{"nctId":"NCT04346277","phase":"","title":"Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","status":"NO_LONGER_AVAILABLE","sponsor":"Implicit Bioscience","startDate":"","conditions":"COVID, ARDS, Human, Ards","enrollment":""},{"nctId":"NCT04842435","phase":"PHASE2, PHASE3","title":"Clinical Study in the Treatment of Patients With Moderate Course of COVID-19","status":"UNKNOWN","sponsor":"Microgen","startDate":"2021-04-12","conditions":"COVID-19","enrollment":376},{"nctId":"NCT04351152","phase":"PHASE3","title":"Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19","status":"UNKNOWN","sponsor":"Humanigen, Inc.","startDate":"2020-05-05","conditions":"Coronavirus Disease 2019 (COVID-19) Pneumonia","enrollment":520},{"nctId":"NCT04395170","phase":"PHASE2, PHASE3","title":"Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.","status":"UNKNOWN","sponsor":"Lifefactors Zona Franca, SAS","startDate":"2020-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":75},{"nctId":"NCT04361552","phase":"PHASE3","title":"Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2020-04-07","conditions":"Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure","enrollment":""},{"nctId":"NCT02529072","phase":"PHASE1","title":"Nivolumab With DC Vaccines for Recurrent Brain Tumors","status":"COMPLETED","sponsor":"Gary Archer Ph.D.","startDate":"2016-01","conditions":"Malignant Glioma, Astrocytoma, Glioblastoma","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-COVID-19 human immunoglobulin","genericName":"Anti-COVID-19 human immunoglobulin","companyName":"Lifefactors Zona Franca, SAS","companyId":"lifefactors-zona-franca-sas","modality":"Biologic","firstApprovalDate":"","aiSummary":"Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus. Used for Prevention of COVID-19 in individuals at high risk of severe disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}